Blog

My plan is switching me to a biosimilar: what should I ask?

Questions to ask when a plan prefers a biosimilar over your injectable or infusion biologic: what it is, interchangeability, exceptions, monitoring and cost.

A letter, a portal message or a call from the pharmacy says your plan now prefers a biosimilar version of the injectable or infused drug you have been taking. You have not changed your condition, your doctor or your plan. Yet the product in the box is about to change. People in this spot usually have the same handful of worries: is it the same medicine, can the plan force the change, what if it does not work for me, and will it cost more or less.

This post is organized as the questions to ask, with what a good answer looks like and who gives it. The prescriber answers the medical questions, the plan or its pharmacy benefit manager answers the coverage questions, and the pharmacy answers the delivery questions. Nothing here tells you whether to accept or refuse a switch.

What a biosimilar is

1. What is a biosimilar, and how is it different from a generic?

A biologic is a medicine made from living cells, such as many drugs for rheumatoid arthritis, psoriasis, inflammatory bowel disease, diabetes, multiple sclerosis and cancer. It is a large, complex molecule, and no two batches are identical even from the same maker. A generic drug copies a small chemical molecule exactly. A biologic cannot be copied exactly.

A biosimilar is a follow-on product that the FDA has found to be highly similar to an approved biologic (the "reference product"), with no clinically meaningful difference in safety, purity or potency. To get there, the maker compares the biosimilar to the reference product at the molecular level, in lab studies and in clinical testing, and the FDA reviews the evidence. A biosimilar is held to that standard, which is more demanding than the test used for a generic. It is not simply a cheaper copy, and it is not a different drug class either.

The practical meaning for you: the biosimilar is expected to work as the reference product does, but it is a different product with a different name, sometimes a different delivery device and sometimes a different list of inactive ingredients.

2. What does "interchangeable" mean?

"Interchangeable" is an additional FDA designation for some biosimilars. Under the law, an interchangeable biosimilar may be substituted for the reference product at the pharmacy without the prescriber writing a new prescription, subject to state pharmacy laws about substitution and notification. A biosimilar that is not designated interchangeable is still an FDA-approved biosimilar. It simply cannot be swapped at the counter without the prescriber's involvement.

The designation has been a topic of change. The FDA has said in recent years that it expects to require fewer extra studies to earn it, and that it views approved biosimilars as safe and effective alternatives either way. The FDA publishes a reference list of biological products, called the Purple Book, that shows which products are biosimilar or interchangeable. Your prescriber or pharmacist can check the specific product, and the information changes as products are approved.

Your plan's preference does not depend on this designation. A plan can prefer a biosimilar on its list of covered drugs whether or not it is interchangeable. The designation affects the pharmacy's ability to substitute, not the plan's ability to prefer.

3. Why is my plan switching me?

The usual reason is cost. A plan, or the pharmacy benefit manager that manages its drug benefit, negotiates prices and rebates with drug makers. A biosimilar may carry a lower net price, or the arrangement for one product may be better than for another. The plan then prefers that product on its formulary and may stop covering, or may add restrictions to, the others. The guide what pharmacy benefit managers do and why they matter describes why this happens.

This is not a statement about your health. It is a coverage decision about which products the plan will pay for. That is why the exception route in questions 6 and 7 exists.

Is the switch forced?

4. Can the plan make me switch in the middle of the year?

It depends on the plan type and the rules that apply. Many plans make formulary changes at the start of a plan year, and plans must generally tell members in advance when they remove or restrict a drug. Plans may also change coverage during the year in some situations, for example when a new product comes onto the market. How much notice and whether you can stay on your current drug until the year ends depend on the plan. Medicare drug plans follow specific notice and transition rules set by CMS. Marketplace, employer and Medicaid plans each follow their own rules, and employer plans that are self-funded follow federal employer-plan rules rather than state insurance rules.

Do this: find the date the change takes effect in the notice, find out whether the notice offers a transition supply, and ask the plan what happens to a fill that falls between the notice and the effective date. If you are in a Medicare plan, a State Health Insurance Assistance Program counselor (see SHIP) can explain the notice rules for your situation.

5. Will I get a transition fill so I do not run out?

Many plans offer a temporary supply of a drug that is newly excluded or restricted, to give you and your prescriber time to switch or request an exception. Whether yours does, and how much it gives, varies. For an injectable on a four-week or monthly cycle, one missed shipment is a missed dose, so ask early. Ask: "Is there a transition or continuity-of-care fill for my current product, and how do I get it?" Then ask the specialty pharmacy the same question, because the pharmacy is the one that will ship.

If you are in the middle of treatment with a hard-to-time schedule, such as an infusion booked weeks ahead, tell the prescriber's office right away, because it may need to reschedule or arrange a different route for the first dose.

Asking to stay on your current drug

6. Can I keep my current drug?

Often there is a way to ask. The request is a formulary exception, sometimes called a continuity-of-care or medical exception. The prescriber submits it, with the reasons the preferred product is not appropriate for you. Plans differ in what they accept. Reasons that appear in plan policies include:

  • You are stable on the current product after other treatments failed, and a change carries a documented risk for you.
  • You have had an allergy, a reaction or an intolerance to something in the biosimilar, and it is documented.
  • You tried the biosimilar and it did not work as well, or you had side effects.
  • The biosimilar's device or dosing is not suitable for you, for example because of dexterity, a vision issue or the need for a different dose strength.

A plain preference to stay put is a weaker basis, though some plans allow continuity for people stable on a drug. Ask the plan: "What are the criteria for an exception to stay on the reference product?" The reply should be specific.

7. What does my doctor need to do?

The prescriber's office usually handles the request, and you can speed it up. Ask the office to:

  1. Send the exception request or prior authorization to the plan, using the plan's form or portal, and note the date.
  2. State in the letter why the preferred biosimilar is not appropriate, citing the specific history (what you took, for how long, what happened).
  3. Ask for an expedited review if a delay would put you at risk of a gap in treatment.
  4. Keep a copy and follow up in a week by phone.

The prior authorization and claim tracker helps you log dates and reference numbers. If the answer is no, the guide what to do when your plan will not cover a drug you need explains the appeal steps, and external review can follow.

Medical questions for your prescriber

8. Are the side effects the same, and what should I watch for?

For biosimilars the FDA has found no clinically meaningful differences in safety and effectiveness, so the expected side-effect profile is the same as the reference product. People still sometimes report new reactions after a switch, such as injection-site reactions, headaches or fatigue, which can come from the device, the inactive ingredients, the injection technique or, in some cases, a "nocebo" effect, in which expecting a worse result produces symptoms. These are real experiences and deserve a hearing.

Ask the prescriber: "What should I watch for after the first dose? What symptoms mean I should call you? Do you want a lab test or a visit after the switch?" For drugs monitored with blood tests or scans, ask whether the monitoring schedule changes. Keep a simple log: the date of each dose, any symptoms and any change in how the condition feels, which is the kind of record that helps if you later ask for an exception.

9. Is switching back and forth safe?

That is a question for your prescriber, who knows your condition. A switch in one direction is common. Multiple switches or a switch back are less studied for some products, and plan preferences can change again the next year. Ask the prescriber how they would handle another switch, and whether they want to consolidate on one product.

10. What about my device or infusion?

Biosimilars can come in different devices (autoinjector pens, prefilled syringes, vials for infusion) and different concentrations. Ask for training on the new device, and ask whether the dose, injection site or timing changes. For an infused biologic given at a clinic, ask who stocks and bills the product, because that determines which benefit pays, which is a separate topic covered in why is my injection billed to my medical benefit and not my pharmacy benefit?.

What it costs and who delivers

11. Will my out-of-pocket cost change?

It may go down, stay the same or even rise, so ask for the numbers instead of assuming. The tier of the preferred biosimilar may be lower than the reference product's tier, which lowers a copay. With coinsurance, the percentage applies to the product's price, and a lower price lowers your share. Yet a plan's design sometimes means the preferred product's cost sharing is the same as the one it replaces. And once the plan drops coverage of the old product, staying on it without an exception can mean paying the full price.

Ask the plan: "What is my cost share for the preferred biosimilar and for my current product, in dollars per fill, and how does each count toward my deductible and out-of-pocket maximum?" Do not guess from the drug name; ask for the exact product.

12. What about the manufacturer's copay card?

Drug makers often offer copay assistance program cards for people with commercial insurance. Whether the maker of the biosimilar has one, what it covers and whether it requires you to use a certain pharmacy are specific to the product, and the rules change. Programs of this kind generally cannot be used by people in Medicare or Medicaid, because of federal rules about inducements. If your plan has a copay accumulator or maximizer, the coupon may not count toward your deductible and may run out partway through the year. copay accumulators and maximizers: why coupons may not count describes how this works, and How to find out if my plan has a copay accumulator before I enroll shows how to check before you rely on one.

13. Will I have to use a different pharmacy?

Plans commonly require specialty drugs to come from a specialty pharmacy the plan or its pharmacy benefit manager designates. A switch of product can come with a switch of pharmacy, a new intake call and a new first-shipment schedule. The walkthrough in from prescription to first dose of a specialty drug: what to expect lists what usually happens, and you can use that sequence to ask the pharmacy about timing.

A sample list of questions to bring

For the plan or PBM:

  1. Which product do you now prefer, and on what date does the change take effect?
  2. Is there a transition fill, and how do I get it?
  3. What are the criteria for an exception to stay on my current product?
  4. What are my costs on each product, and how do they count toward my deductible and out-of-pocket maximum?
  5. Which pharmacy must ship it, and is there a deadline to move?

For the prescriber:

  1. Do you consider the switch appropriate for me, and why or why not?
  2. What should I watch for, and when should I call?
  3. Will you file an exception if I want to stay, and what do you need from me?
  4. What happens if the biosimilar does not work for me?

For the pharmacy:

  1. Is the product in my hand the one my prescriber ordered, and does the device differ?
  2. Who trains me on the new device?
  3. When is my next shipment, and what do I do if it is late?

If the answer is no

If the plan denies your exception, you can usually appeal internally and then ask for an independent external review. The denial notice tells you the deadline, which for most plans is at least 180 days. Keep your dose log, ask the prescriber for a stronger letter and, if your care is at risk of an interruption, ask for an expedited review. If you believe the plan is not following its own documents, the state insurance department takes complaints about insured plans, and your employer's benefits team can help if the plan is self-funded.

Key takeaways

  • A biosimilar is a highly similar, FDA-approved follow-on to a biologic, held to a stricter standard than a generic. "Interchangeable" is an extra FDA designation that affects pharmacy-level substitution, not whether a plan may prefer it.
  • A plan's preference is mainly a cost and contracting decision. It is not a medical judgment about you, which is why an exception route exists.
  • Ask for the effective date, a transition fill, the exception criteria and your exact cost on each product before the old drug stops being covered.
  • Medical questions on side effects, monitoring, devices and switching back belong with your prescriber. Keep a dose and symptom log.
  • Check the copay card and any accumulator rules, and ask which pharmacy will ship. A denied exception can be appealed and sent to external review.

Terms used in this guide

Related tools

Related guides

Latest on this topic